Protalix BioTherapeutics (PLX) Other Non-Current Liabilities (2011 - 2021)
Protalix BioTherapeutics' quarterly Other Non-Current Liabilities came in at $38000.0 in Q2 2021, down 69.35% year-on-year from $124000.0 in Q2 2020, and up 46.15% quarter-over-quarter from $26000.0 in Q1 2021.
Protalix BioTherapeutics has reported Other Non-Current Liabilities for 8 years, with the latest figure at $38000.0 in Q2 2021.
- For the quarter ending Q2 2021, Other Non-Current Liabilities fell 69.35% year-over-year to $38000.0; the trailing twelve-month figure through Jun 2021 stood at $38000.0 (down 69.35% YoY), and the FY2020 full-year result was $51000.0, down 89.98% from the prior year.
- Other Non-Current Liabilities for Q2 2021 stood at $38000.0, up from $26000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $6.2 million in Q3 2018, with the low at $26000.0 in Q1 2021.
- Average Other Non-Current Liabilities over 5 years is $2.9 million, with a median of $5.1 million recorded in 2017.
- Year-over-year, Other Non-Current Liabilities rose 17.44% in 2017 and tumbled 99.14% in 2020.
- Tracing PLX's Other Non-Current Liabilities over 5 years: stood at $5.1 million in 2017, then rose by 4.77% to $5.3 million in 2018, then slumped by 90.38% to $509000.0 in 2019, then slumped by 89.98% to $51000.0 in 2020, then slipped by 25.49% to $38000.0 in 2021.
- The last three Other Non-Current Liabilities figures came in at $38000.0 (Q2 2021), $26000.0 (Q1 2021), and $51000.0 (Q4 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 38,000.00 |
| Mar 31, 2021 | 26,000.00 |
| Dec 31, 2020 | 51,000.00 |
| Sep 30, 2020 | 46,000.00 |
| Jun 30, 2020 | 124,000.00 |
| Mar 31, 2020 | 210,000.00 |
| Dec 31, 2019 | 509,000.00 |
| Sep 30, 2019 | 5.37 Mn |
| Jun 30, 2019 | 5.35 Mn |
| Mar 31, 2019 | 5.29 Mn |
| Dec 31, 2018 | 5.29 Mn |
| Sep 30, 2018 | 6.15 Mn |
| Jun 30, 2018 | 5.26 Mn |
| Mar 31, 2018 | 5.17 Mn |
| Dec 31, 2017 | 5.05 Mn |
| Dec 31, 2016 | 4.30 Mn |
| Mar 31, 2012 | 5.62 Mn |
| Dec 31, 2011 | 6.57 Mn |